2022 World Conference on Lung Cancer (ePosters)-EP08.01-002. Real-World Survival Outcomes of Patients with High PD-L1 Advanced NSCLC Who Received Chemo-Immunotherapy vs Immunotherapy

EP08.01-002. Real-World Survival Outcomes of Patients with High PD-L1 Advanced NSCLC Who Received Chemo-Immunotherapy vs Immunotherapy

Back to course

Pdf Summary

This document presents the results of a real-world retrospective cohort study conducted in three Australian hospitals to compare the survival outcomes of patients with high PD-L1 advanced non-small cell lung cancer (NSCLC) who received chemotherapy-immunotherapy combination (pembro-chemo) versus immunotherapy alone (pembro alone). The study included patients with stage IV NSCLC, no sensitizing EGFR/ALK/ROS1 mutation, and PD-L1 expression ≥50%. The primary endpoint was overall survival (OS), and secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and adverse events (AEs).<br /><br />The study found that there was no significant difference in OS or PFS between the pembro-chemo group and the pembro alone group. Multivariate analysis also showed no difference in OS when adjusted for certain prognostic factors. However, the ORR was higher in the pembro-chemo group compared to the pembro alone group. It is important to note that the pembro-chemo treatment was associated with higher rates of hospitalizations, indicating the need for caution in its use.<br /><br />The baseline characteristics of the patients included in the study were also presented, including age, sex, ECOG baseline, histology, smoking history, and the presence of metastases. The Kaplan-Meier analysis of OS and PFS showed favorable outcomes for patients receiving first-line pembrolizumab with or without chemotherapy compared to chemotherapy alone.<br /><br />The study concludes that first-line pembrolizumab with or without chemotherapy has superior efficacy compared to chemotherapy alone in patients with high PD-L1 advanced NSCLC. The addition of chemotherapy to pembrolizumab alone remains uncertain. The findings of this study contribute to the understanding of the real-world effectiveness of different treatment approaches for advanced NSCLC.<br /><br />It is worth noting that the study has references to two previous publications, which may provide additional context and information on the topic.

Asset Subtitle

Junipearl Cheng

Meta Tag

Speaker Junipearl Cheng

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

retrospective cohort study

advanced non-small cell lung cancer

PD-L1 expression

chemotherapy-immunotherapy combination

immunotherapy alone

overall survival

progression-free survival

objective response rate

adverse events

baseline characteristics